Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05147233 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
A Phase 3 study of Inflammation Eye Pain and Postoperative Cataract, sponsored by Oculis.
- Completed
- Registry status
- Phase 3
- Development phase
- 241
- Enrollment target
- 20
- Study locations
NCT05147233 is a Phase 3 study of Inflammation Eye Pain and Postoperative Cataract that has completed, run by Oculis. The registered enrollment target is 241 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT05147233, a Phase 3 study of Inflammation Eye Pain and Postoperative Cataract, has completed, sponsored by Oculis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 241 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG OCS-01
Study Locations (20)
California
- Oculis Site 9 - Inglewood
- Oculis Site 23 - Newport Beach
- Oculis Site 26 - Petaluma
- Oculis Site 24 - San Pedro
- Oculis Site 22 - Westminster
Arizona
- Oculis Site 16 - Chandler
- Oculis Site 28 - Phoenix
Missouri
- Oculis Site 5 - St Louis
- Oculis Site 3 - Washington
Ohio
- Oculis Site 6 - Brecksville
- Oculis Site 14 - Cincinnati
Arkansas
- Oculis Site 8 - Fayetteville
Colorado
- Oculis Site 11 - Fort Collins
Florida
- Oculis Site 12 - Tamarac
Georgia
- Oculis Site 17 - Morrow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2022-06-24 |
| Est. Completion | 2023-07-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05147233
The ClinicalTrials.gov registry entry for NCT05147233 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oculis, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Inflammation Eye Pain appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT05147233 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Arizona, Missouri.
Frequently Asked Questions
What is clinical trial NCT05147233 about?
NCT05147233 is a clinical study titled "A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery". This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
What is the current status of trial NCT05147233?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 241 participants. The study started on 2022-06-24. Estimated completion is 2023-07-03.
What conditions does trial NCT05147233 study?
This clinical trial studies the following conditions: Inflammation Eye Pain, Postoperative Cataract.
What interventions are being tested in trial NCT05147233?
The interventions under investigation include: Vehicle (DRUG), OCS-01 (DRUG).
Who is sponsoring clinical trial NCT05147233?
This trial is sponsored by Oculis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05147233 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.